Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients

[1]  R. Fan,et al.  Coat color determination by miR-137 mediated down-regulation of microphthalmia-associated transcription factor in a mouse model. , 2012, RNA.

[2]  H. Hoekstra,et al.  The current status of S-100B as a biomarker in melanoma. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  Zhaolei Zhang,et al.  Evidence for Positive Selection on a Number of MicroRNA Regulatory Interactions during Recent Human Evolution , 2012, PLoS genetics.

[4]  MD Frcpa Rajmohan Murali MBBS,et al.  Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma , 2012, Annals of Surgical Oncology.

[5]  R. Camp,et al.  Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome , 2011, Clinical Cancer Research.

[6]  G. Ghanem,et al.  TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome , 2011, British Journal of Cancer.

[7]  Álvaro González,et al.  Evaluation of multiple serum markers in advanced melanoma , 2011, Tumor Biology.

[8]  John P A Ioannidis,et al.  Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. , 2011, Journal of the National Cancer Institute.

[9]  M. Martinka,et al.  Prognostic Significance of Cytoplasmic p27 Expression in Human Melanoma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[10]  A. Eggermont,et al.  Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. , 2011, European journal of cancer.

[11]  B. Monsarrat,et al.  Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma , 2010, Experimental dermatology.

[12]  Jeffrey E Gershenwald,et al.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Khayat,et al.  Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. , 2009, European journal of cancer.

[15]  D. Munn,et al.  Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice , 2009, The Journal of Immunology.

[16]  E. Erdei,et al.  Melanoma epidemiology and public health. , 2009, Dermatologic clinics.

[17]  D. Hunter,et al.  Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians , 2009, International journal of cancer.

[18]  D. Hicklin,et al.  Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. , 2008, Human antibodies.

[19]  F. Marincola,et al.  A gene expression signature associated with survival in metastatic melanoma , 2006, Journal of Translational Medicine.

[20]  T. Alonzo.  Standards for reporting prognostic tumor marker studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Alexander D. MacKerell,et al.  Design of Inhibitors for S100B. , 2005, Current topics in medicinal chemistry.

[22]  C. Gundy,et al.  Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma , 2005, Clinical Cancer Research.

[23]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[24]  M. Green,et al.  The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Wakamatsu,et al.  Tyrosinase-related proteins suppress tyrosinase-mediated cell death of melanocytes and melanoma cells. , 2004, Experimental cell research.

[26]  P. Morel,et al.  Evaluation of the serum l-dopa/l-tyrosine ratio as a melanoma marker , 2003, Melanoma research.

[27]  R. Halaban,et al.  Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. , 2003, Cancer research.

[28]  D. Tyler,et al.  Thin Melanomas: Predictive Lethal Characteristics From a 30-Year Clinical Experience , 2003, Annals of surgery.

[29]  G. D. de Gast,et al.  Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma , 2003, Melanoma research.

[30]  Y. Tsuji,et al.  Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF. , 2002, Nucleic acids research.

[31]  R. Boissy,et al.  Tyrp1 and oculocutaneous albinism type 3. , 2001, Pigment cell research.

[32]  A. Eggermont,et al.  On the release and half‐life of S100B protein in the peripheral blood of melanoma patients , 2001, International journal of cancer.

[33]  G. Imokawa,et al.  Tyrosinase Stabilization by Tyrp1 (the brown Locus Protein)* , 1998, The Journal of Biological Chemistry.

[34]  C. Heizmann,et al.  Calcium regulation of Ndr protein kinase mediated by S100 calcium‐binding proteins , 1998, The EMBO journal.

[35]  A. Houghton,et al.  A melanosomal membrane protein is a cell surface target for melanoma therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.